ZIMMER BIOMET HOLDINGS, INC. (ZBH) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does ZIMMER BIOMET HOLDINGS, INC. Do?
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana. ZIMMER BIOMET HOLDINGS, INC. (ZBH) is classified as a large-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Bryan C. Hanson and employs approximately 18,000 people, headquartered in Warsaw, Indiana. With a market capitalization of $17.8B, ZBH is one of the prominent companies in the Healthcare sector.
ZIMMER BIOMET HOLDINGS, INC. (ZBH) Stock Rating — Hold (April 2026)
As of April 2026, ZIMMER BIOMET HOLDINGS, INC. receives a Hold rating with a composite score of 47.2/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.ZBH ranks #1,629 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ZIMMER BIOMET HOLDINGS, INC. ranks #146 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
ZBH Stock Price and 52-Week Range
ZIMMER BIOMET HOLDINGS, INC. (ZBH) currently trades at $93.12. The stock gained $0.09 (0.1%) in the most recent trading session. The 52-week high for ZBH is $114.44, which means the stock is currently trading -18.6% from its annual peak. The 52-week low is $84.59, putting the stock 10.1% above its annual trough. Recent trading volume was 1.8M shares, reflecting moderate market activity.
Is ZBH Overvalued or Undervalued? — Valuation Analysis
ZIMMER BIOMET HOLDINGS, INC. (ZBH) carries a value factor score of 67/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 21.67x, compared to the Healthcare sector average of 23.63x — a discount of 8%. The price-to-book ratio stands at 1.39x, versus the sector average of 2.75x. The price-to-sales ratio is 2.26x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, ZBH trades at 8.70x EV/EBITDA, versus 6.34x for the sector.
Overall, ZBH's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
ZIMMER BIOMET HOLDINGS, INC. Profitability — ROE, Margins, and Quality Score
ZIMMER BIOMET HOLDINGS, INC. (ZBH) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 6.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 3.5% versus the sector average of -33.1%.
On a margin basis, ZIMMER BIOMET HOLDINGS, INC. reports gross margins of 71.3%, compared to 71.5% for the sector. The operating margin is 15.7% (sector: -66.1%). Net profit margin stands at 10.5%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 3.1% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
ZBH Debt, Balance Sheet, and Financial Health
ZIMMER BIOMET HOLDINGS, INC. has a debt-to-equity ratio of 82.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.98x, suggesting adequate working capital coverage. Total debt on the balance sheet is $8.11B. Cash and equivalents stand at $1.29B.
ZBH has a beta of 0.38, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for ZIMMER BIOMET HOLDINGS, INC. is 80/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.
ZIMMER BIOMET HOLDINGS, INC. Revenue and Earnings History — Quarterly Trend
In TTM 2026, ZIMMER BIOMET HOLDINGS, INC. reported revenue of $7.81B and earnings per share (EPS) of $3.56. Net income for the quarter was $817M. Gross margin was 71.3%. Operating income came in at $1.22B.
In FY 2025, ZIMMER BIOMET HOLDINGS, INC. reported revenue of $8.23B and earnings per share (EPS) of $3.56. Net income for the quarter was $705M. Gross margin was 69.7%. Revenue grew 7.2% year-over-year compared to FY 2024. Operating income came in at $1.10B.
In Q3 2025, ZIMMER BIOMET HOLDINGS, INC. reported revenue of $2.00B and earnings per share (EPS) of $1.17. Net income for the quarter was $231M. Gross margin was 72.0%. Revenue grew 9.7% year-over-year compared to Q3 2024. Operating income came in at $351M.
In Q2 2025, ZIMMER BIOMET HOLDINGS, INC. reported revenue of $2.08B and earnings per share (EPS) of $0.77. Net income for the quarter was $153M. Gross margin was 71.5%. Revenue grew 7.0% year-over-year compared to Q2 2024. Operating income came in at $300M.
Over the past 8 quarters, ZIMMER BIOMET HOLDINGS, INC. has demonstrated a growth trajectory, with revenue expanding from $1.94B to $7.81B. Investors analyzing ZBH stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
ZBH Dividend Yield and Income Analysis
ZIMMER BIOMET HOLDINGS, INC. (ZBH) currently pays a dividend yield of 1.0%. At this yield, a $10,000 investment in ZBH stock would generate approximately $$98.00 in annual dividend income. The net margin of 10.5% provides reasonable coverage for the dividend, though investors should monitor payout sustainability.
ZBH Momentum and Technical Analysis Profile
ZIMMER BIOMET HOLDINGS, INC. (ZBH) has a momentum factor score of 37/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 32/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 18/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
ZBH vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, ZIMMER BIOMET HOLDINGS, INC. (ZBH) ranks #146 out of 838 stocks based on the Blank Capital composite score. This places ZBH in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing ZBH against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ZBH vs S&P 500 (SPY) comparison to assess how ZIMMER BIOMET HOLDINGS, INC. stacks up against the broader market across all factor dimensions.
ZBH Next Earnings Date
No upcoming earnings date has been announced for ZIMMER BIOMET HOLDINGS, INC. (ZBH) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy ZBH? — Investment Thesis Summary
ZIMMER BIOMET HOLDINGS, INC. presents a balanced picture with arguments on both sides. The value score of 67/100 suggests attractive pricing relative to fundamentals. Momentum is weak at 37/100, a headwind for near-term performance. Low volatility (stability score 80/100) reduces downside risk.
In summary, ZIMMER BIOMET HOLDINGS, INC. (ZBH) earns a Hold rating with a composite score of 47.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ZBH stock.
Related Resources for ZBH Investors
Explore more research and tools: ZBH vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ZBH head-to-head with peers: ZBH vs AZN, ZBH vs SLGL, ZBH vs VMD.